drugset
Drugs / Movantik
last change Aug 2017 re-read 3 minutes ago

Movantik

Developed for
opioid-induced constipation

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) MOVANTIK — 2014-09-16 fda.gov ↗

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 4 NCT03060512 Comparator Mar → Aug 2017 opioid-induced constipation AstraZeneca Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Movantik ClinicalTrials.gov intervention name — accepted as the source's own label NCT03060512 ↗
Action Inhibit “We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation.” PMID 24896818 ↗ Jun 2014
Route Oral “Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.” NCT03060512 ↗